Novartis gets U.S. nod for long-delayed Amgen copycat

Novartis on Tuesday won U.S. approval for its long-delayed version of Amgen's $4 billion seller Neulasta drug, helping the Swiss drugmaker in its uphill battle to sell copies of rivals' blockbusters in the world's top drug market.

from Reuters: Health News https://ift.tt/2WTrc6R